Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (CRBP)

Historical Holders from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CRBP on Nasdaq
Shares outstanding
17,552,178
Price per share
$8.14
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
8,624,593
Total reported value
$109,102,058
% of total 13F portfolios
0%
Share change
-259,945
Value change
-$2,067,263
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
78
Price from insider filings
$11.46
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (CRBP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Cormorant Asset Management, LP 13% +4.2% $24,434,598 -$312,902 2,344,971 -1.3% Cormorant Asset Management, LP 11 Dec 2025
CITADEL ADVISORS LLC 5.3% $12,405,011 980,610 Kenneth Griffin 04 Nov 2025
ORBIMED ADVISORS LLC 5.9% $5,307,498 718,200 OrbiMed Capital LLC 31 Dec 2024
VANGUARD GROUP INC 4.9% $4,136,516 599,495 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.9% $2,431,622 352,409 BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (CRBP) has 78 institutional shareholders filing 13F forms. They hold 8,624,593 shares. of 17,552,178 outstanding shares (49%) .

Top 25 institutional shareholders own 46% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Cormorant Asset Management, LP 14% 2,375,000 0% 2.1% $30,043,750
ORBIMED ADVISORS LLC 6.7% 1,172,287 0% 0.36% $14,829,431
Octagon Capital Advisors LP 6.4% 1,115,000 0% 2.2% $14,104,750
VANGUARD GROUP INC 3.5% 612,030 +2.1% 0% $7,742,180
Prosight Management, LP 2% 343,400 -41% 1% $4,344,010
Exome Asset Management LLC 1.3% 229,962 -17% 2% $2,909,019
BlackRock, Inc. 1.3% 226,898 -36% 0% $2,870,258
COMERICA BANK 1.1% 200,001 0% 0.01% $2,530,013
ARMISTICE CAPITAL, LLC 1.1% 192,000 0% 0.08% $2,428,800
Aberdeen Group plc 1.1% 188,231 +161% 0% $2,381,122
MORGAN STANLEY 0.88% 154,842 -2.6% 0% $1,958,752
MILLENNIUM MANAGEMENT LLC 0.78% 136,429 -14% 0% $1,725,827
GEODE CAPITAL MANAGEMENT, LLC 0.73% 127,731 -4.7% 0% $1,616,489
TANG CAPITAL MANAGEMENT LLC 0.73% 127,520 0% 0.06% $1,613,128
HighVista Strategies LLC 0.67% 118,027 +57% 0.37% $1,493,041
RENAISSANCE TECHNOLOGIES LLC 0.61% 107,200 -30% 0% $1,356,080
MARSHALL WACE, LLP 0.58% 102,509 +416% 0% $1,296,738
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 0.49% 85,826 -28% 0% $1,085,699
Assenagon Asset Management S.A. 0.49% 85,347 0% $1,079,640
ACADIAN ASSET MANAGEMENT LLC 0.48% 83,819 -45% 0% $1,059,000
AMERIPRISE FINANCIAL INC 0.4% 69,625 0% $880,756
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.39% 69,246 +60% 0% $875,962
PRELUDE CAPITAL MANAGEMENT, LLC 0.38% 66,984 -17% 0.07% $847,348
Velan Capital Investment Management LP 0.35% 61,000 +3.4% 0.72% $771,650
UBS Group AG 0.34% 59,496 -35% 0% $752,624

Institutional Holders of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (CRBP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 188,943 $1,537,996 +$835,237 813.99% 3
2025 Q3 8,624,593 $109,102,058 -$2,067,263 1,265% 78
2025 Q2 9,061,852 $62,525,276 -$8,932,514 690% 78
2025 Q1 10,430,351 $55,391,632 -$13,394,437 531% 85
2024 Q4 10,952,105 $129,272,235 -$16,308,014 1,180% 98
2024 Q3 11,745,584 $242,331,671 -$44,650,435 2,063% 106
2024 Q2 10,752,925 $486,116,698 +$101,256,908 4,525% 107
2024 Q1 8,529,313 $334,743,519 +$310,281,997 3,924% 81
2023 Q4 749,666 $4,528,896 +$40,967 604% 32
2023 Q3 742,967 $5,007,338 +$30,936 674% 26
2023 Q2 739,439 $5,797,676 +$132,453 784% 28
2023 Q1 723,148 $5,257,408 +$5,257,398 727% 28
2020 Q2 0 $0 -$5,240 0
2020 Q1 1,000 $5,240 524% 1
2019 Q4 1,000 $5,460 546% 1